君实生物 · Junshi Biosciences
← News archive

· Regulatory update

China approves intravenous toripalimab combination for urothelial carcinoma

China’s National Medical Products Administration approved intravenous toripalimab with disitamab vedotin for first-line treatment of locally advanced or metastatic HER2-expressing urothelial carcinoma.

The approval was based on the Phase 3 RC48-C016 trial, registered as NCT05302284.

Read the full company release